...
首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >Unilateral renal cell carcinoma with coexistent renal disease: a rare cause of end-stage renal disease.
【24h】

Unilateral renal cell carcinoma with coexistent renal disease: a rare cause of end-stage renal disease.

机译:单侧肾细胞癌并存肾脏疾病:终末期肾脏疾病的罕见原因。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Renal cell carcinoma (RCC) is a disorder encompassing a wide spectrum of pathological renal lesions. Coexistence of unilateral RCC and associated pathology in the contralateral kidney is an unusual and challenging therapeutic dilemma that can result in renal failure. So far, data on unilateral RCC with chronic renal failure necessitating renal replacement therapy have not been published. The aim of the present study was to evaluate the incidence of end-stage renal disease (ESRD) from unilateral RCC, and to assess the associated pathology and possible pathogenic factors. METHODS: In 1999, a survey of the 350 patients treated by chronic dialysis in Asturias, Spain, was carried out to identify and collect clinical information on patients with primary unilateral RCC whilst on their renal replacement programme. RESULTS: Seven patients were identified as having ESRD and unilateral RCC, giving an incidence of 2% of patients treated by dialysis. There was a wide spectrum of associated disease and clinical presentation. All patients underwent radical or partial nephrectomy and were free of recurrence 6--64 months after surgery. Six patients were alive and free of malignancy recurrence for 6--30 months after the onset of haemodialysis. CONCLUSION: ESRD is rare in association with unilateral RCC, but does contribute to significant morbidity. However, the data presented here are encouraging and suggest that cancer-free survival with renal replacement therapy can be achieved in such patients.
机译:背景:肾细胞癌(RCC)是一种涵盖多种病理性肾脏病变的疾病。对侧肾脏中单侧RCC和相关病理的共存是一种异常且具有挑战性的治疗难题,可导致肾衰竭。迄今为止,尚未发表需要进行肾脏替代治疗的慢性肾功能衰竭的单侧RCC数据。本研究的目的是评估单侧RCC终末期肾脏疾病(ESRD)的发生率,并评估相关的病理学和可能的致病因素。方法:1999年,对西班牙阿斯图里亚斯接受慢性透析治疗的350例患者进行了一项调查,以鉴定和收集有关原发性单侧RCC患者的肾脏替代计划的临床信息。结果:七名患者被确定患有ESRD和单侧RCC,占透析治疗患者的2%。有广泛的相关疾病和临床表现。所有患者均接受了根治性或部分性肾切除术,术后6--64个月无复发。血液透析开始后6--30个月,有6名患者活着并且没有恶性肿瘤复发。结论:ESRD很少与单侧RCC相关,但确实会导致严重的发病。但是,此处提供的数据令人鼓舞,并表明在此类患者中可以通过肾脏替代疗法实现无癌生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号